The Life Sciences team advised TRex Bio with respect to IP matters and its underlying patent strategy on its initial public offering of approximately 8.3 million shares of common stock at a public offering price of $14 per share. The offering is expected to generate approximately $116.7 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses. The underwriters have an option to purchase approximately 1.3 million additional shares at the initial public offering price, which could increase gross proceeds by approximately $17.5 million if exercised in full. TRex Bio’s shares are expected to begin trading on the Nasdaq under the ticker symbol “TRXB” on October 9, 2026.
TRex Bio is developing immunoregulatory medicines designed to restore immune balance in autoimmune and inflammatory diseases. By addressing the disease where it presents, in the tissue, TRex Bio’s goal is to promote tissue repair for more durable disease control.
The Goodwin team was led by Kevin Kabler and Mayim Wiens.
For more information on the deal, please read coverage in Fierce Biotech.